P162 Investigating triggers, preventers, and progression of symptoms in flares of systemic autoimmune rheumatic diseases: a mixed methods study
Notice bibliographique
Résumé
Abstract Background/Aims The INSPIRE (Investigating Neuropsychiatric Symptom Prevalence and Impact in Rheumatology patient Experiences) study found a high self-reported prevalence of neuropsychiatric symptoms. Identification of patterns of prodromal and during flare symptoms could assist in earlier identification and treatment of impending flares. Patterns of symptom progression can be challenging to identify in clinic, particularly due to time constraints and neuropsychiatric symptoms being highly under-reported by patients and under-estimated by clinicians. The INSPIRE study highlighted the importance of giving a higher value to patient experiences and symptom interpretation. In the next phase of the INSPIRE study, we are: 1)Analysing the patterns (both within and between-patient) of prodromes and progression of neuropsychiatric and other organ system symptoms in systemic autoimmunerheumatic diseases (SARDs); 2) Investigating different triggers and “preventers/reducers” of flares; 3) Exploring how patients identify their personal triggers, preventers, prodromes and progression of symptoms in a flare, and whether/how this identification helps them, and their clinicians, manage flares. Methods Working in full partnership with SARD patients, informed by existing literature and the first INSPIRE cohort, we have devised a survey which asks about experiences of a wide-ranging list of triggers, preventers and prodromes. In addition to the - previously often overlooked - neuropsychiatric symptoms identified in INSPIRE 1, symptoms from all organ systems and psychosocial factors will be incorporated into INSPIRE 2. Data from this survey will be used to assess and compare (using t-tests, ANOVA, and thematic analysis) prevalence and clustering of different triggers, preventers and prodromes between SARDs. We are also currently conducting interviews with patients from a range of SARD groups, ethnicities, ages, and genders to explore their progression of symptoms, experiences of managing flares and adapting to living with their disease. Quantitative and qualitative methods are being integrated at several stages of the research process. Results We received >800 responses from the INSPIRE 1 cohort to open-ended questions about their flare symptoms, triggers and preventers/reducers. Triggers and preventers were numerous and diverse, and a trigger for one patient was sometimes a preventer for another (e.g. heat). With multidisciplinary team input, these have been categorized into factors including: pharmacological, dietary, biological, environmental, and psychosocial. A similar process of categorization has occurred for the diverse range of symptoms. Questions have been compiled for the INSPIRE 2 survey which will be widely distributed internationally to SARD patients. Conclusion Based on the rapid recruitment and positive response from SARD patients to previous surveys from this research team, a minimum sample size of N = 1500 is anticipated. Analysis will occur in early 2025. Highly novel results are anticipated in this currently under-researched area, and will be presented at the conference. Disclosure M. Piper: None. J.A. Bourgeois: None. T.A. Pollak: None. A. Tunks: None. L. Calderwood: None. E. Dalby: None. L. Andreoli: Consultancies; consultancy fees/ speaker fees from: Eli Lilly, Glaxo Smith Kline, Janssen, Novartis, UCB, and Werfen Group. A. Bortoluzzi: None. F. Naughton: None. A. Kaul: None. S. Taylor: None. J. Brimicombe: None. K. Naidu: None. X. Yan: None. D. D’Cruz: Corporate appointments; Leadership position on the APS charity board. Consultancies; consultancy/speaker fees from GSK, Eli Lilly, Vifor and UCB. M. Sloan: None.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,017 | 0,019 |
| Méta-épidémiologie (sens strict) | 0,001 | 0,001 |
| Méta-épidémiologie (sens large) | 0,001 | 0,003 |
| Bibliométrie | 0,002 | 0,002 |
| Études des sciences et des technologies | 0,001 | 0,001 |
| Communication savante | 0,002 | 0,002 |
| Science ouverte | 0,001 | 0,002 |
| Intégrité de la recherche | 0,001 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,006 | 0,001 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».